GLP-1, , (Red Flag)
It remains in clinical trials and is still undergoing rigorous research and safety testing
Call 999 or go to your nearest A&E immediately if you experience: Signs of a severe allergic reaction (anaphylaxis), including swelling of the face, lips, tongue, or throat, difficulty breathing, or a widespread rash with collapse Seek urgent medical advice if you experience: Severe or persistent vomiting that prevents you from keeping fluids down Signs of dehydration, including dizziness, dark urine, or significantly reduced urination Severe abdominal pain, particularly if it radiates to the back this may indicate pancreatitis, a rare but serious adverse effect associated with GLP-1 receptor agonists [11] [12] Pain in the upper right abdomen, fever, yellowing of the skin or eyes (jaundice), pale stools, or dark urine these may be signs of a gallbladder problem, such as gallstones or cholecystitis, which have been associated with this class of medicine and with rapid weight loss Symptoms of hypoglycaemia (low blood sugar), such as shakiness, sweating, confusion, or palpitations the risk is higher if you are also taking insulin or a sulfonylurea
Important pharmacologic and practical differences Route and formulation / absorption issues Since semaglutide is a peptide, it can be broken down in the stomach by proteolytic enzymes, which limits its natural bioavailability
Counselling patients with uterine fibroids: a review of the management and complications
Tirzepatide has shown the largest results so far, with average reductions ranging from 15% to nearly 21% over 72 weeks, depending on dose
